Home > Boards > US Listed > Biotechs > Motif Bio plc (MTFB) (MTFB)

LOVE IT!! The Company also has plans to

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
$$$MADE Member Profile
 
Followed By 69
Posts 1,845
Boards Moderated 2
Alias Born 04/18/17
160x600 placeholder
Notice of Effectiveness (effect) Edgar (US Regulatory) - 12/30/2019 6:00:54 AM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 12/23/2019 4:31:03 PM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 12/23/2019 4:30:47 PM
Notification Filed by a National Securities Exchange to Report the Removal From Listing and Registration of Matured , Redeeme... Edgar (US Regulatory) - 12/9/2019 4:46:04 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 11/27/2019 6:16:24 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 11/26/2019 6:15:54 AM
Motif Bio plc Announces Voluntary Delisting from the Nasdaq Capital Market GlobeNewswire Inc. - 11/26/2019 2:00:10 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 11/18/2019 9:10:58 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 11/15/2019 6:26:43 AM
Antimicrobials Working Group Commends Senator Isakson and Senator Casey for Introducing Legislation to Improve Access to Inno... PR Newswire (US) - 6/7/2019 9:27:00 AM
Motif Bio to Present Iclaprim Data at ASM Microbe 2019 GlobeNewswire Inc. - 5/21/2019 2:00:00 AM
Motif Bio meeting with U.S. FDA held as planned GlobeNewswire Inc. - 5/3/2019 1:25:00 PM
Motif Bio Signs Agreement with Lamellar Biomedical GlobeNewswire Inc. - 5/1/2019 2:00:00 AM
Motif Bio plc: Notice of Annual General Meeting GlobeNewswire Inc. - 4/26/2019 2:01:00 AM
Motif Bio Announces Appointment of Andrew Powell to Board of Directors GlobeNewswire Inc. - 4/26/2019 2:00:00 AM
Motif Bio Presents New Iclaprim Data at ECCMID 2019 GlobeNewswire Inc. - 4/16/2019 2:00:00 AM
Motif Bio Reports Fiscal Year 2018 Results GlobeNewswire Inc. - 4/15/2019 2:00:00 AM
Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology a... PR Newswire (US) - 4/12/2019 10:08:00 AM
Motif Bio to Present Iclaprim Data at ECCMID 2019 GlobeNewswire Inc. - 4/4/2019 2:00:00 AM
Motif Bio Granted Meeting with U.S. FDA regarding Iclaprim GlobeNewswire Inc. - 3/20/2019 3:00:00 AM
Motif Bio Announces Appointment of Bruce Williams as Interim Chairman and Resignation of Richard Morgan from the Board GlobeNewswire Inc. - 3/18/2019 3:00:00 AM
Motif Bio Conference Call and Webcast GlobeNewswire Inc. - 2/19/2019 2:00:00 AM
Motif BioSciences Enters into Amendment Agreement with Hercules Capital GlobeNewswire Inc. - 2/18/2019 2:00:00 AM
Motif Bio Receives Complete Response Letter from the FDA GlobeNewswire Inc. - 2/14/2019 2:00:00 AM
$$$MADE   Wednesday, 03/20/19 02:18:09 PM
Re: None
Post # of 46 
LOVE IT!! The Company also has plans to develop iclaprim for hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), as there is a high unmet need for new therapies in this indication. A Phase 2 trial in patients with HABP has been successfully completed and a Phase 3 trial is being planned. Additionally, iclaprim has been granted orphan drug designation by the FDA for the treatment of Staphylococcus aureus lung infections in patients with cystic fibrosis and is in preclinical development for this indication. Iclaprim has received Qualified Infectious Disease Product (QIDP) designation from the FDA together with Fast Track status for the ABSSSI indication. If approved for the ABSSSI indication as a New Chemical Entity, iclaprim will be eligible for 10 years of market exclusivity in the U.S. from the date of first approval, under the Generating Antibiotic Incentives Now Act (the GAIN Act). In Europe, 10 years of market exclusivity is anticipated. Motif is also building a patent estate to provide additional protection for iclaprim and has two U.S. method of use patents issued that will expire in 2037.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist